What is the risk of death in elderly users of conventional vs atypical antipsychotic medications?
The FDA issued a black box warning over two decades ago regarding the increased risk of death associated with atypical antipsychotic use in elderly dementia patients. This raised urgent questions about comparative safety, addressing the crucial topic: what is the risk of death in elderly users of conventional vs atypical antipsychotic medications?